nference Zepbound frailty study in older adults; LIPFENDRA launch details ($315/month, pharmacy benefit); House China deadline passed; PCAC docket closes Wednesday.
Read digest →House China Committee July 17 deadline arrives today; Merck LIPFENDRA analyst coverage; Novartis Fabhalta traditional approval in IgAN; PCAC 6 days out.
Read digest →FDA approves Merck's oral PCSK9 macrocyclic peptide enlicitide (56-59% LDL reduction, $315/month); Boehringer BI 3034701 triple agonist to Phase 2; House China deadline arrives.
Read digest →AAIC 2026 closes: Lilly Kisunla titration and long-term extension; NewAmsterdam obicetrapib p-tau217 wins; Roche Elecsys pTau217 primary care data; SOTIO SOT109 ADC FDA Fast Track.
Read digest →AAIC 2026 Tuesday: Biogen CELIA full data (primary endpoint miss, tau/cognition wins); LEQEMBI LEADER 17-month real-world data; Lilly P-tau217 blood test; Veru sarcopenic-obesity summit.
Read digest →AAIC 2026 Monday: Vaccinex pepinemab glial biomarker session; Voyager VY1706 75% tau reduction at 6 months; Eisai etalanetug reduces MTBR-tau243; Longeveron laromestrocel data; Pfizer obesity discovery VP.
Read digest →AAIC 2026 opens in London: Denali plenary on BBB delivery, LEQEMBI SC autoinjector data, Voyager tau AAV, Biogen diranersen, Acumen sabirnetug; CNBC employer coverage stuck at 36%.
Read digest →AAIC 2026 opens Sunday July 12 in London; Gallup 11% GLP-1 usage / 36.4% obesity rate; Novartis-Myricx $1.5B ADC deal; Lonza-Nona BBB deal.
Read digest →MindRank $52M Series B for oral GLP-1 MDR-001; White House FDA commissioner review; WaPo peptide showdown; AZ/Ionis Wainua Phase 3 miss; China trial letters.
Read digest →PCAC written-comment member-review closes today; NPR feature on peptide push; Rhythm TRANSCEND setmelanotide in NEJM; HIMS analyst spread; oral GLP-1 tracker.
Read digest →Axios: Chinese fentanyl makers pivot to peptides; Kalohexis IPO on MC3R/MC4R obesity; FDA 23 novel approvals; Vera Trutakna approved; PCAC comment cutoff Jul 9.
Read digest →Vivani and Novo partner on a semaglutide implant, Kailera's oral GLP-1 clears Phase 3 in China, and a JAMA study finds online GLP-1 prescribing fast and loose.
Read digest →Jerome Adams pitches a regulated 503A middle path for peptides, Medicare GLP-1 Bridge denials trace to a billing code, and Lantheus draws an edotreotide CRL.
Read digest →KFF projects Bridge cost $1.3-10B; Sandoz generic tirzepatide ANDAs accepted; Knoepfler 'stacked' quote; BPC-157 pipeline retrospective ahead of PCAC.
Read digest →Novo Millar statement on Wegovy Bridge access; Pep Club telehealth launch; US News/AP FDA scientists warning; PolitiFact retatrutide primer; Bridge Day 2.
Read digest →Medicare GLP-1 Bridge launches at $50/month; 3.8M eligible per KFF; 4 questions linger per Becker's; Public Citizen and BioCentury oppose peptide deregulation.
Read digest →FDA scientists flag insufficient evidence on 7 peptides; STAT scoops PCAC panelist conflicts; oral testimony closes today; Medicare Bridge launches July 1.
Read digest →FDA 503B GLP-1 comments close today; Medicare Bridge media wave; PCAC testimony Tuesday; Zymeworks-Theravance $929M; pharmacist guidance; HIMS analyst notes.
Read digest →